Results 151 to 160 of about 1,458 (206)
Some of the next articles are maybe not open access.
A review of olopatadine for the treatment of ocular allergy
Expert Opinion on Pharmacotherapy, 2004Ocular allergy affects > 20% of the general population and many therapeutic preparations are available to individuals experiencing the most common forms--seasonal and perennial allergic conjunctivitis. 0.1% Olopatadine topical ophthalmic solution is currently approved for the treatment of allergic signs and symptoms in patients > or = 3 years of age ...
Mark B Abelson
exaly +3 more sources
Allergy and Asthma Proceedings, 2018
GSP301 is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate developed as a single nasal spray.To assess the relative bioavailability of olopatadine administered as GSP301 versus two olopatadine monotherapy nasal spray formulations.In this single-dose, open-label, crossover study, healthy ...
Sudeesh K Tantry, Piyush Patel
exaly +3 more sources
GSP301 is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate developed as a single nasal spray.To assess the relative bioavailability of olopatadine administered as GSP301 versus two olopatadine monotherapy nasal spray formulations.In this single-dose, open-label, crossover study, healthy ...
Sudeesh K Tantry, Piyush Patel
exaly +3 more sources
A review of the use of olopatadine in allergic conjunctivitis
International Ophthalmology, 2004 Ocular allergies are very common and range in intensity from mild, self-resolving, acute conditions to serious, chronic disease that can severely affect vision. The vast majority of sufferers experience relatively mild symptoms, which are often seasonal in nature. Treatments should be simple, comfortable and very safe. They should be able to respond to
McGill, James I.
openaire +4 more sources
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old.
openaire +2 more sources
Ocular allergy treatment comparisons: Azelastine and olopatadine
Current Allergy and Asthma Reports, 2004Azelastine hydrochloride 0.05% and olopatadine hydrochloride 0.1% are topical ocular allergy treatments that have demonstrated multiple pharmacologic actions, including antihistamine, mast cell stabilization, and inhibition of proinflammatory mediators.
Leonard, Bielory +2 more
openaire +2 more sources
Azelastine and olopatadine in the treatment of allergic rhinitis
Annals of Allergy, Asthma & Immunology, 2009To review the literature supporting current recommendations for nasal antihistamines as first-line therapy for allergic rhinitis.Published articles in the peer-reviewed medical literature.Clinical trials focusing on the efficacy, safety, and recommended uses of the currently approved nasal antihistamines in the United States: azelastine nasal spray, 0 ...
openaire +2 more sources
Olopatadine nasal spray for the treatment of allergic rhinitis
Expert Review of Clinical Immunology, 2010Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity.
Peter S, Roland +2 more
openaire +2 more sources
Safety and Tolerability of Olopatadine 0.2% in Children and Adolescents
Journal of Ocular Pharmacology and Therapeutics, 2007The aim of this study was to evaluate the safety of olopatadine hydrochloride ophthalmic solution 0.2% in children and adolescents 3-17 years of age.In this 6-week, randomized, double-masked safety evaluation, eligible subjects with asymptomatic eyes underwent in-office visits at weeks 1, 3, and 6 and were contacted by telephone at weeks 2, 4, and 5 ...
Steven J, Lichtenstein +5 more
openaire +2 more sources
Effects of olopatadine in limited scleroderma with peripheral eosinophils
Geriatrics & Gerontology International, 2008Scleroderma and eosinophilia often occur together, though the pathogenesis is unclear. We investigated the effect of olopatadine hydrochloride in a series of cases of limited scleroderma (LS). Ten patients with LS and positive eosinophil counts (LSE) were enrolled (average age, 85 years; six men and four women).
Motoo, Kikuchi +4 more
openaire +2 more sources